RORA and gastric cancer: Low mRNA expression of RORα was associated with a better prognosis in clinical stages 2 and 4 in patients with GC [stage 2: HR = 2.13, 95% CI: (1.18–3.86), P = 0.01; stage 4: HR = 1.99, 95% CI: (1.37–2.97), P = 0.00056].